Last reviewed · How we verify

Standard of Care Oral antipsychotics

University of Utah · FDA-approved active Small molecule

Standard of Care Oral antipsychotics is a Antipsychotic Small molecule drug developed by University of Utah. It is currently FDA-approved for Schizophrenia, Bipolar disorder, Psychotic disorders.

Standard of care oral antipsychotics block dopamine and/or serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.

Standard of care oral antipsychotics block dopamine and/or serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder, Psychotic disorders.

At a glance

Generic nameStandard of Care Oral antipsychotics
SponsorUniversity of Utah
Drug classAntipsychotic
TargetDopamine D2 receptor; Serotonin 5-HT2A receptor
ModalitySmall molecule
Therapeutic areaPsychiatry
PhaseFDA-approved

Mechanism of action

Oral antipsychotics work primarily through antagonism of dopamine D2 receptors, which reduces hyperactivity in dopaminergic pathways associated with psychosis. Many also have serotonin 5-HT2A receptor antagonism, which contributes to antipsychotic and mood-stabilizing effects. The class includes both first-generation (typical) agents that are primarily dopamine antagonists and second-generation (atypical) agents with broader receptor profiles.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Standard of Care Oral antipsychotics

What is Standard of Care Oral antipsychotics?

Standard of Care Oral antipsychotics is a Antipsychotic drug developed by University of Utah, indicated for Schizophrenia, Bipolar disorder, Psychotic disorders.

How does Standard of Care Oral antipsychotics work?

Standard of care oral antipsychotics block dopamine and/or serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.

What is Standard of Care Oral antipsychotics used for?

Standard of Care Oral antipsychotics is indicated for Schizophrenia, Bipolar disorder, Psychotic disorders, Acute agitation in psychiatric patients.

Who makes Standard of Care Oral antipsychotics?

Standard of Care Oral antipsychotics is developed and marketed by University of Utah (see full University of Utah pipeline at /company/university-of-utah).

What drug class is Standard of Care Oral antipsychotics in?

Standard of Care Oral antipsychotics belongs to the Antipsychotic class. See all Antipsychotic drugs at /class/antipsychotic.

What development phase is Standard of Care Oral antipsychotics in?

Standard of Care Oral antipsychotics is FDA-approved (marketed).

What are the side effects of Standard of Care Oral antipsychotics?

Common side effects of Standard of Care Oral antipsychotics include Extrapyramidal symptoms (tremor, rigidity, akathisia), Weight gain, Metabolic syndrome (hyperglycemia, dyslipidemia), Sedation, Prolactin elevation, Orthostatic hypotension.

What does Standard of Care Oral antipsychotics target?

Standard of Care Oral antipsychotics targets Dopamine D2 receptor; Serotonin 5-HT2A receptor and is a Antipsychotic.

Related